ea0092op-09-02 | Oral Session 9: Thyroid Eye Disease | ETA2023
Foster Kelly
, Dickinson Brent
, Bedian Vahe
Objective: Evidence shows that IGF-1 receptor (IGF-1R) antagonism reduces the inflammation and proptosis that occur in thyroid eye disease (TED). VRDN-001 is a full antagonist to IGF-1R, and VRDN-003 is a next-generation, half-life extended version of VRDN-001 designed to enable subcutaneous (SC) administration. We compared the in vivo pharmacokinetic (PK) parameters of VRDN-001 and VRDN-003 and used a PK model to simulate potential VRDN-003 SC dosing regimens.<p ...